- Home
- ELVN vs FHI Comparison
ELVN vs FHI Comparison
Compare ELVN & FHI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | ELVN | FHI |
|---|---|---|
| Founded | 2016 | 1955 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Investment Managers |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 4.2B | 4.2B |
| IPO Year | 2020 | 1998 |
Fundamental Metrics
Financial Performance| Metric | ELVN | FHI |
|---|---|---|
| Price | $40.83 | $56.15 |
| Analyst Decision | Strong Buy | Hold |
| Analyst Count | 14 | 8 |
| Target Price | ★ $73.67 | $59.43 |
| AVG Volume (30 Days) | ★ 1.5M | 667.2K |
| Earning Date | 11-11-2026 | 10-29-2026 |
| Dividend Yield | N/A | ★ 2.69% |
| EPS Growth | 3.17 | ★ 58.82 |
| EPS | N/A | ★ 2.65 |
| Revenue | N/A | ★ $1,102,924,000.00 |
| Revenue This Year | N/A | $10.53 |
| Revenue Next Year | N/A | $3.58 |
| P/E Ratio | ★ N/A | $21.35 |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $14.79 | $46.66 |
| 52 Week High | $62.32 | $67.20 |
Technical Indicators
Market Signals| Indicator | ELVN | FHI |
|---|---|---|
| Relative Strength Index (RSI) | 23.68 | 38.02 |
| Support Level | $38.58 | $54.83 |
| Resistance Level | $43.05 | $57.11 |
| Average True Range (ATR) | 1.84 | 1.19 |
| MACD | -0.34 | 0.09 |
| Stochastic Oscillator | 16.51 | 30.41 |
Price Performance
Historical ComparisonAbout ELVN Enliven Therapeutics Inc.
Enliven Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the discovery and development of small molecule therapeutics. The product candidates of the company include ELVN-001 is designed to specifically target the BCR-ABL fusion gene product, the oncogenic driver for patients with chronic myeloid leukemia (CML), ELVN-002 is designed to inhibit wild-type HER2 and key mutations of HER2.
About FHI Federated Hermes Inc.
Federated Hermes provides asset management services for institutional and individual investors. The firm had $911.6 billion in managed assets at the end of the second quarter of 2026, composed of equity (12%), multi-asset (less than 1%), fixed-income (11%), alternative (2%), and money market (74%) funds. The company's cash management operations are expected to generate around 52% of Federated's revenue this year, compared with 30%, 10%, and 8%, respectively, for the equity, fixed-income, and alternatives/multi-asset/other operations. The company's products are distributed via trust banks, wealth managers, and retail broker/dealers (67% of AUM), institutional investors (26%), and international clients (7%).